Treatment with ZYKADIA may cause GI Adverse Reactions, Hepatic and Embryo-fetal Toxicities, Interstitial Lung Disease/Pneumonitis, QTc Interval Prolongation, Hyperglycemia, Bradycardia, Pancreatiti...
View information for patients starting treatment with ZYKADIA® (ceritinib).
Help your eligible patients access ZYKADIA by filling out the personal information and insurance sections of this form.
ZYKADIA® (ceritinib) capsules is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
IMPORTANT SAFETY INFORMATION for ZYKADIA® (ceritinib) capsules
Gastrointestinal Adverse Reactions
Interstitial Lung Disease/Pneumonitis
QTc Interval Prolongation
Effect of Other Drugs on Ceritinib
Effect of Ceritinib on Other Drugs